BSE Live
Mar 13, 16:01Prev. Close
1325.25
Open Price
1319.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 13, 15:59Prev. Close
1324.30
Open Price
1324.30
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1314.70 (5)
| Cash Flow of Cipla (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 6,174.16 | 5,432.14 | 3,626.44 | 3,905.08 | 3,350.66 | |
| Net CashFlow From Operating Activities | 3,300.99 | 3,726.77 | 3,035.05 | 2,773.43 | 3,460.31 | |
| Net Cash Used In Investing Activities | -2,308.53 | -2,882.82 | -2,757.95 | -2,463.73 | -3,360.45 | |
| Net Cash Used From Financing Activities | -1,073.93 | -708.83 | -424.77 | -426.72 | -65.80 | |
| Foreign Exchange Gains / Losses | -0.31 | -0.08 | -0.14 | -0.41 | -0.88 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -81.78 | 135.04 | -147.81 | -117.43 | 33.18 | |
| Cash And Cash Equivalents Begin of Year | 164.52 | 29.48 | 177.29 | 294.72 | 261.54 | |
| Cash And Cash Equivalents End Of Year | 82.74 | 164.52 | 29.48 | 177.29 | 294.72 |
04.03.2026
Cipla to form JV with Kemwell Biopharma; share price down marginally
04.03.2026
23.02.2026
29.01.2026
27.01.2026
Cipla Consolidated December 2025 Net Sales at Rs 7,074.48 crore, up 0.02% Y-o-Y
27.01.2026
Cipla Standalone December 2025 Net Sales at Rs 4,498.08 crore, down 9.51% Y-o-Y
10.11.2025
Cipla Standalone September 2025 Net Sales at Rs 5,225.72 crore, up 9.44% Y-o-Y
03.11.2025
Cipla Consolidated September 2025 Net Sales at Rs 7,589.44 crore, up 7.64% Y-o-Y
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
09.05.2024
17.04.2024
Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities
12.07.2023
28.01.2025
30.10.2024
Multiple near-term challenges may hijack Cipla's growth trajectory
13.05.2024
06.11.2018
Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings
15.03.2026
13.03.2026
13.03.2026
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth